Abstract
In an attempt to form a hypothesis (not yet verified) regarding the most active medical treatment in benign prostatic hyperplasia, a randomised study was carried out on three groups, evaluating a minimun of 4 months therapy. 52 patients received Finasteride (Group A), 43 received Alfuzosina (Group B) and 42 were treated with an association of Finasteride and Alfuzosina (Group C). There was a statistically significant variation in all the assessed urodynamic parameters, except for micturitional resistance, where group B showed more benefit than group C and group C more than group A. However, clinical evaluation was only able to positively judge the influence of the three therapy groups on the I-PSS improvement, among other things not correlated to the variation in obstruction parameters, which although showing definite improvement, mostly remained in the pathological range.
Get full access to this article
View all access options for this article.